# Peptide Receptor Radionuclide Therapy (PRRT) in Tumors With High Expression of Somatostatin Receptors (Phase 2)

> **NCT04790708** · NA · UNKNOWN · sponsor: **University Hospital of Ferrara** · enrollment: 250 (estimated)

## Conditions studied

- Neuroendocrine Tumors
- Peptide Receptor Radionuclide Therapy (PRRT)

## Interventions

- **RADIATION:** Lutetium-177 (177Lu)-DOTATOC
- **RADIATION:** Yttrium-90 (90Y)-DOTATOC
- **RADIATION:** 177Lu-DOTATOC + 90Y-DOTATOC
- **RADIATION:** Re-treatment 177Lu-DOTATOC
- **RADIATION:** Re-treatment 90Y-DOTATOC

## Key facts

- **NCT ID:** NCT04790708
- **Lead sponsor:** University Hospital of Ferrara
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-07-02
- **Primary completion:** 2023-06-30
- **Final completion:** 2023-06-30
- **Target enrollment:** 250 (ESTIMATED)
- **Last updated:** 2021-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04790708

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04790708, "Peptide Receptor Radionuclide Therapy (PRRT) in Tumors With High Expression of Somatostatin Receptors (Phase 2)". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT04790708. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*